TWI319324B - The use of anti-estrogens for the prevention and treatment of androgen-deprivation induced osteoporosis, loss of bone mineral density and/or bone fractures in males subjects with prostate cancer
- Google Patents
The use of anti-estrogens for the prevention and treatment of androgen-deprivation induced osteoporosis, loss of bone mineral density and/or bone fractures in males subjects with prostate cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gtx IncfiledCriticalGtx Inc
Priority to TW94124310ApriorityCriticalpatent/TWI319324B/en
Publication of TW200536555ApublicationCriticalpatent/TW200536555A/en
Application grantedgrantedCritical
Publication of TWI319324BpublicationCriticalpatent/TWI319324B/en
TW94124310A2002-12-162002-12-16The use of anti-estrogens for the prevention and treatment of androgen-deprivation induced osteoporosis, loss of bone mineral density and/or bone fractures in males subjects with prostate cancer
TWI319324B
(en)
The use of anti-estrogens for the prevention and treatment of androgen-deprivation induced osteoporosis, loss of bone mineral density and/or bone fractures in males subjects with prostate cancer
The use of anti-estrogens for the prevention and treatment of androgen-deprivation induced osteoporosis, loss of bone mineral density and/or bone fractures in males subjects with prostate cancer
The use of anti-estrogens for the prevention and treatment of androgen-deprivation induced osteoporosis, loss of bone mineral density and/or bone fractures in males subjects with prostate cancer
The use of toremifene for the prevention and treatment of androgen-deprivation induced osteoporosis, loss of bone mineral density and/or bone fractures in males subjects with prostate cancer
The use of anti-estrogens for the prevention and treatment of androgen-deprivation induced osteoporosis, loss of bone mineral density and/or bone fractures in males subjects with prostate cancer